{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:22:35Z","timestamp":1792804955721,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The Swedish Inflammatory Bowel Disease Registry (SWIBREG) includes approximately 84% of all patients with inflammatory bowel disease (IBD) treated with immunomodulators, biologics or surgery in Sweden. Data on health-related quality of life (HRQoL) have been collected using EQ-5D-5L in the registry since 2012. Nevertheless, there are few studies assessing the validity of EQ-5D-5L in this patient population. Thus, the aim of this study was to assess the construct validity of EQ-5D-5L amongst patients with IBD (ulcerative colitis and Crohn\u2019s disease).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Individual-level data on EQ-5D-5L and other disease-specific measures were extracted from SWIBREG. Known-groups validity was assessed by analysing whether the EQ-5D-5L captured expected differences between patient groups with different activity levels of the disease. Convergent validity was assessed by analysing whether the reported problems in the dimensions of EQ-5D-5L, EQ VAS, and the EQ-5D-5L index value correlated, as hypothesized, with the four dimensions in the Short Health Scale, a symptom index question, and the Physician Global Assessment (PGA) score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 9769 patients with IBD were included in the study. Patients with active IBD reported more health problems in the EQ-5D-5L descriptive system than patients being in remission. The effect sizes for the differences in reported problems between patients with active and inactive disease were at least small (\u22650.1) or medium (\u22650.3) in all dimensions except self-care. Differences in the mean EQ-5D-5L index and EQ-VAS score between patients with active and inactive disease were statistically significant (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and larger than pre-defined cut-offs for minimally important differences (&gt;0.08 for the index and &gt;11.0 for EQ-VAS). The analysis of convergent validity showed that EQ-5D-5L results correlated as expected with the disease-specific measures in 16 of the 21 analyses. In total, 22 (79%) of the 28 hypotheses were supported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings support the construct validity of EQ-5D-5L amongst patients with IBD and contribute to the scarce literature on the validity of the five-level version of EQ-5D in this patient population. These findings have important implications for the choice of HRQoL measure in routine health care registries like SWIBREG as well as for future clinical or health economic studies considering using EQ-5D-5L as a measure of HRQoL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00709-9","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T08:01:53Z","timestamp":1711526513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Construct validity of EQ-5D-5L among patients with inflammatory bowel disease\u2014a study based on real-world data from the Swedish Inflammatory Bowel Disease Registry"],"prefix":"10.1186","volume":"8","author":[{"given":"Jack","family":"Latteur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Ernstsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evalill","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"J\u00e4ghult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0715-7591","authenticated-orcid":false,"given":"Emelie","family":"Heintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"10080","key":"709_CR1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn\u2019s disease. Lancet 389(10080):1741\u20131755. https:\/\/doi.org\/10.1016\/S0140-6736(16)31711-1","journal-title":"Lancet"},{"issue":"18","key":"709_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C (2011) Ulcerative colitis. N Engl J Med 365(18):1713\u20131725. https:\/\/doi.org\/10.1056\/NEJMra1102942","journal-title":"N Engl J Med"},{"issue":"12","key":"709_CR3","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","volume":"65","author":"M Gajendran","year":"2019","unstructured":"Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG (2019) A comprehensive review and update on ulcerative colitis. Dis Mon 65(12):100851. https:\/\/doi.org\/10.1016\/j.disamonth.2019.02.004","journal-title":"Dis Mon"},{"key":"709_CR4","doi-asserted-by":"publisher","unstructured":"GBD 2017 Inflammatory Bowel Disease Collaborators (2020) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5(1):17\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(19)30333-4","DOI":"10.1016\/S2468-1253(19)30333-4"},{"issue":"1","key":"709_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/apt.12528","volume":"39","author":"K Busch","year":"2014","unstructured":"Busch K, Ludvigsson JF, Ekstrom-Smedby K, Ekbom A, Askling J, Neovius M (2014) Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther 39(1):57\u201368. https:\/\/doi.org\/10.1111\/apt.12528","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"709_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/BF01538073","volume":"34","author":"DA Drossman","year":"1989","unstructured":"Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI (1989) Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci 34(9):1379\u20131386. https:\/\/doi.org\/10.1007\/BF01538073","journal-title":"Dig Dis Sci"},{"issue":"3","key":"709_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00004836-198806000-00014","volume":"10","author":"A Mitchell","year":"1988","unstructured":"Mitchell A, Guyatt G, Singer J, Irvine EJ, Goodacre R, Tompkins C, Williams N, Wagner F (1988) Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 10(3):306\u2013310. https:\/\/doi.org\/10.1097\/00004836-198806000-00014","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"709_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jval.2011.08.004","volume":"15","author":"R Leidl","year":"2012","unstructured":"Leidl R, Reitmeir P, Konig HH, Stark R (2012) The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease. Value Health 15(1):151\u2013157. https:\/\/doi.org\/10.1016\/j.jval.2011.08.004","journal-title":"Value Health"},{"issue":"5","key":"709_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ibd\/izy015","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Keefer L, Wilding H, Hewitt C, Graff LA, Mikocka-Walus A (2018) Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Inflamm Bowel Dis 24(5):966\u2013976. https:\/\/doi.org\/10.1093\/ibd\/izy015","journal-title":"Inflamm Bowel Dis"},{"key":"709_CR10","doi-asserted-by":"publisher","unstructured":"Calvino-Suarez C, Ferreiro-Iglesias R, Baston-Rey I, Barreiro-de Acosta M (2021) Role of quality of life as endpoint for inflammatory bowel disease treatment. Int J Environ Res Public Health 18(13). https:\/\/doi.org\/10.3390\/ijerph18137159","DOI":"10.3390\/ijerph18137159"},{"issue":"1","key":"709_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R (1996) EuroQol: the current state of play. Health Policy 37(1):53\u201372. https:\/\/doi.org\/10.1016\/0168-8510(96)00822-6","journal-title":"Health Policy"},{"issue":"3","key":"709_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy"},{"issue":"8","key":"709_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, Busschbach J, Boye KS (2020) Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ 21(8):1245\u20131257. https:\/\/doi.org\/10.1007\/s10198-020-01195-8","journal-title":"Eur J Health Econ"},{"key":"709_CR14","doi-asserted-by":"publisher","unstructured":"Shaw C, Longworth L, Bennett B, McEntee-Richardson L, Shaw JW (2023) A review of the use of EQ-5D for clinical outcome assessment in health technology assessment, regulatory claims, and published literature. Patient. https:\/\/doi.org\/10.1007\/s40271-023-00662-7","DOI":"10.1007\/s40271-023-00662-7"},{"issue":"1","key":"709_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s41687-020-00231-8","volume":"4","author":"O Ernstsson","year":"2020","unstructured":"Ernstsson O, Janssen MF, Heintz E (2020) Collection and use of EQ-5D for follow-up, decision-making, and quality improvement in health care - the case of the Swedish National Quality Registries. J Patient Rep Outcomes 4(1):78. https:\/\/doi.org\/10.1186\/s41687-020-00231-8","journal-title":"J Patient Rep Outcomes"},{"issue":"9","key":"709_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/00365521.2019.1660799","volume":"54","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, Halfvarson J, Hjortswang H, Jaghult S, Karling P, Nordenvall C, Olen O, Olsson M, Rejler M, Strid H, Myrelid P (2019) Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register. Scand J Gastroenterol 54(9):1089\u20131101. https:\/\/doi.org\/10.1080\/00365521.2019.1660799","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"709_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"709_CR18","unstructured":"Fayers PM, Machin D Quality of life: the assessment, analysis and reporting of patient-reported outcomes, Third edn. John Wiley & Sons"},{"key":"709_CR19","doi-asserted-by":"publisher","first-page":"578073","DOI":"10.3389\/fpubh.2020.578073","volume":"8","author":"S Gottschalk","year":"2020","unstructured":"Gottschalk S, Konig HH, Nejad M, Dams J (2020) Psychometric properties of the EQ-5D for the assessment of health-related quality of life in the population of middle-old and oldest-old persons: study protocol for a systematic review. Front Public Health 8:578073. https:\/\/doi.org\/10.3389\/fpubh.2020.578073","journal-title":"Front Public Health"},{"key":"709_CR20","volume-title":"COSMIN study design checklist for patient-reported outcome measurement instruments","author":"LB Mokkink","year":"2019","unstructured":"Mokkink LB, Prinsen CA, Patrick DL, Alonso J, Bouter LM, de Vet HC, Terwee CB (2019) COSMIN study design checklist for patient-reported outcome measurement instruments. COSMIN"},{"issue":"3","key":"709_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1037\/0022-3514.84.3.608","volume":"84","author":"D Westen","year":"2003","unstructured":"Westen D, Rosenthal R (2003) Quantifying construct validity: two simple measures. J Pers Soc Psychol 84(3):608\u2013618. https:\/\/doi.org\/10.1037\/\/0022-3514.84.3.608","journal-title":"J Pers Soc Psychol"},{"key":"709_CR22","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511996214","volume-title":"Measurement in medicine: a practical guide","author":"HC de Vet","year":"2011","unstructured":"de Vet HC, Terwee CB, Mokkink LB, Knol DL (2011) Measurement in medicine: a practical guide. Cambridge University Press, Cambridge"},{"issue":"1","key":"709_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11136-018-2003-4","volume":"28","author":"F Rencz","year":"2019","unstructured":"Rencz F, Lakatos PL, Gulacsi L, Brodszky V, Kurti Z, Lovas S, Banai J, Herszenyi L, Cserni T, Molnar T, Pentek M, Palatka K (2019) Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn\u2019s disease. Qual Life Res 28(1):141\u2013152. https:\/\/doi.org\/10.1007\/s11136-018-2003-4","journal-title":"Qual Life Res"},{"issue":"11","key":"709_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/00042737-200211000-00008","volume":"14","author":"HH Konig","year":"2002","unstructured":"Konig HH, Ulshofer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G, Leidl R (2002) Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 14(11):1205\u20131215. https:\/\/doi.org\/10.1097\/00042737-200211000-00008","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"709_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ibd.20989","volume":"16","author":"RG Stark","year":"2010","unstructured":"Stark RG, Reitmeir P, Leidl R, Konig HH (2010) Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis 16(1):42\u201351. https:\/\/doi.org\/10.1002\/ibd.20989","journal-title":"Inflamm Bowel Dis"},{"key":"709_CR26","unstructured":"SWIBREG (2022) SWIBREG Annual report 2021 (SWIBREG \u00c5rsrapport f\u00f6r 2021)"},{"issue":"5","key":"709_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15(5):708\u2013715. https:\/\/doi.org\/10.1016\/j.jval.2012.02.008","journal-title":"Value Health"},{"issue":"1","key":"709_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12955-022-02083-w","volume":"20","author":"S Sun","year":"2022","unstructured":"Sun S, Chuang LH, Sahlen KG, Lindholm L, Norstrom F (2022) Estimating a social value set for EQ-5D-5L in Sweden. Health Qual Life Outcomes 20(1):167. https:\/\/doi.org\/10.1186\/s12955-022-02083-w","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"709_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40273-020-00905-7","volume":"38","author":"K Burstrom","year":"2020","unstructured":"Burstrom K, Teni FS, Gerdtham UG, Leidl R, Helgesson G, Rolfson O, Henriksson M (2020) Experience-based Swedish TTO and VAS value sets for EQ-5D-5L health states. Pharmacoeconomics 38(8):839\u2013856. https:\/\/doi.org\/10.1007\/s40273-020-00905-7","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"709_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","volume":"22","author":"E Stolk","year":"2019","unstructured":"Stolk E, Ludwig K, Rand K, van Hout B, Ramos-Goni JM (2019) Overview, update, and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol. Value Health 22(1):23\u201330. https:\/\/doi.org\/10.1016\/j.jval.2018.05.010","journal-title":"Value Health"},{"issue":"8","key":"709_CR31","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.crohns.2012.07.030","volume":"7","author":"E McDermott","year":"2013","unstructured":"McDermott E, Keegan D, Byrne K, Doherty GA, Mulcahy HE (2013) The short health scale: a valid and reliable measure of health related quality of life in English speaking inflammatory bowel disease patients. J Crohns Colitis 7(8):616\u2013621. https:\/\/doi.org\/10.1016\/j.crohns.2012.07.030","journal-title":"J Crohns Colitis"},{"issue":"1","key":"709_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ibd.20255","volume":"14","author":"H Stjernman","year":"2008","unstructured":"Stjernman H, Granno C, Jarnerot G, Ockander L, Tysk C, Blomberg B, Strom M, Hjortswang H (2008) Short health scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn\u2019s disease. Inflamm Bowel Dis 14(1):47\u201352. https:\/\/doi.org\/10.1002\/ibd.20255","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"709_CR33","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1080\/00365520600610618","volume":"41","author":"H Hjortswang","year":"2006","unstructured":"Hjortswang H, Jarnerot G, Curman B, Sandberg-Gertzen H, Tysk C, Blomberg B, Almer S, Strom M (2006) The short health scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol 41(10):1196\u20131203. https:\/\/doi.org\/10.1080\/00365520600610618","journal-title":"Scand J Gastroenterol"},{"issue":"26","key":"709_CR34","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/nejm198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 317(26):1625\u20131629. https:\/\/doi.org\/10.1056\/nejm198712243172603","journal-title":"N Engl J Med"},{"key":"709_CR35","doi-asserted-by":"publisher","unstructured":"Kamp KJ, Hawes SE, Tse CS, Singh S, Dang N, Oberai R, Weaver SA, Melmed GY, Siegel CA, van Deen WK, Qorus IBD (2022) Concordance and discordance between patient-reported remission, patient-reported outcomes, and physician global assessment. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izac206","DOI":"10.1093\/ibd\/izac206"},{"issue":"4","key":"709_CR36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00535-022-01862-y","volume":"57","author":"M Kishi","year":"2022","unstructured":"Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T (2022) A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 57(4):246\u2013266. https:\/\/doi.org\/10.1007\/s00535-022-01862-y","journal-title":"J Gastroenterol"},{"key":"709_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1745-6215-8-17","volume":"8","author":"RM Cooney","year":"2007","unstructured":"Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP (2007) Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials 8:17. https:\/\/doi.org\/10.1186\/1745-6215-8-17","journal-title":"Trials"},{"key":"709_CR38","unstructured":"SWIBERG Quality indicators SWIBREG [Kvalitetsindikatorer SWIBREG]."},{"key":"709_CR39","unstructured":"SWIBREG PGA in Swedish [PGA p\u00e5 svenska]. https:\/\/www.swibreg.se\/personal\/wp-content\/uploads\/sites\/3\/2018\/07\/PGA_pa_svenska_mini.pdf"},{"issue":"5","key":"709_CR40","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, Terwee CB (2018) COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res 27(5):1147\u20131157. https:\/\/doi.org\/10.1007\/s11136-018-1798-3","journal-title":"Qual Life Res"},{"issue":"1","key":"709_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012","journal-title":"J Clin Epidemiol"},{"key":"709_CR42","volume-title":"Practical statistics for medical research","author":"DG Altman","year":"1991","unstructured":"Altman DG (1991) Practical statistics for medical research. Chapman and Hall, London"},{"issue":"1","key":"709_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1037\/a0024338","volume":"141","author":"CO Fritz","year":"2012","unstructured":"Fritz CO, Morris PE, Richler JJ (2012) Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 141(1):2\u201318. https:\/\/doi.org\/10.1037\/a0024338","journal-title":"J Exp Psychol Gen"},{"key":"709_CR44","volume-title":"Research methods and statistics in psychology","author":"H Coolican","year":"2014","unstructured":"Coolican H (2014) Research methods and statistics in psychology, Sixth edn. Psychology Press, Taylor & Francis Group, New York","edition":"Sixth edn"},{"issue":"1","key":"709_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J (1992) A power primer. Psychol Bull 112(1):155\u2013159. https:\/\/doi.org\/10.1037\/\/0033-2909.112.1.155","journal-title":"Psychol Bull"},{"issue":"7","key":"709_CR46","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1023\/a:1013171831202","volume":"10","author":"K Burstrom","year":"2001","unstructured":"Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10(7):621\u2013635. https:\/\/doi.org\/10.1023\/a:1013171831202","journal-title":"Qual Life Res"},{"issue":"2","key":"709_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11136-013-0496-4","volume":"23","author":"K Burstrom","year":"2014","unstructured":"Burstrom K, Sun S, Gerdtham UG, Henriksson M, Johannesson M, Levin LA, Zethraeus N (2014) Swedish experience-based value sets for EQ-5D health states. Qual Life Res 23(2):431\u2013442. https:\/\/doi.org\/10.1007\/s11136-013-0496-4","journal-title":"Qual Life Res"},{"issue":"4","key":"709_CR48","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/cts.12178","volume":"7","author":"RM Kaplan","year":"2014","unstructured":"Kaplan RM, Chambers DA, Glasgow RE (2014) Big data and large sample size: a cautionary note on the potential for bias. Clin Transl Sci 7(4):342\u2013346. https:\/\/doi.org\/10.1111\/cts.12178","journal-title":"Clin Transl Sci"},{"issue":"4","key":"709_CR49","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/mlr.0b013e3181c162a2","volume":"48","author":"N Luo","year":"2010","unstructured":"Luo N, Johnson J, Coons SJ (2010) Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care 48(4):365\u2013371. https:\/\/doi.org\/10.1097\/mlr.0b013e3181c162a2","journal-title":"Med Care"},{"issue":"9","key":"709_CR50","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/j.1365-2036.2009.03966.x","volume":"29","author":"G Coteur","year":"2009","unstructured":"Coteur G, Feagan B, Keininger DL, Kosinski M (2009) Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn\u2019s disease. Aliment Pharmacol Ther 29(9):1032\u20131041. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.03966.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"709_CR51","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11136-012-0344-y","volume":"22","author":"BB Reeve","year":"2013","unstructured":"Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, Schwartz C, Revicki DA, Moinpour CM, McLeod LD, Lyons JC, Lenderking WR, Hinds PS, Hays RD, Greenhalgh J, Gershon R, Feeny D, Fayers PM, Cella D, Brundage M, Ahmed S, Aaronson NK, Butt Z (2013) ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 22(8):1889\u20131905. https:\/\/doi.org\/10.1007\/s11136-012-0344-y","journal-title":"Qual Life Res"},{"issue":"3","key":"709_CR52","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s11136-018-2048-4","volume":"28","author":"EKH Chan","year":"2019","unstructured":"Chan EKH, Edwards TC, Haywood K, Mikles SP, Newton L (2019) Implementing patient-reported outcome measures in clinical practice: a companion guide to the ISOQOL user\u2019s guide. Qual Life Res 28(3):621\u2013627. https:\/\/doi.org\/10.1007\/s11136-018-2048-4","journal-title":"Qual Life Res"},{"issue":"4","key":"709_CR53","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s11136-006-9153-5","volume":"16","author":"DA Revicki","year":"2007","unstructured":"Revicki DA, Gnanasakthy A, Weinfurt K (2007) Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. Qual Life Res 16(4):717\u2013723. https:\/\/doi.org\/10.1007\/s11136-006-9153-5","journal-title":"Qual Life Res"},{"issue":"1","key":"709_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s41687-019-0171-9","volume":"3","author":"PJ van der Wees","year":"2019","unstructured":"van der Wees PJ, Verkerk EW, Verbiest MEA, Zuidgeest M, Bakker C, Braspenning J, de Boer D, Terwee CB, Vajda I, Beurskens A, van Dulmen SA (2019) Development of a framework with tools to support the selection and implementation of patient-reported outcome measures. J Patient Rep Outcomes 3(1):75. https:\/\/doi.org\/10.1186\/s41687-019-0171-9","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"709_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/joim.12409","volume":"279","author":"E Nilsson","year":"2016","unstructured":"Nilsson E, Orwelius L, Kristenson M (2016) Patient-reported outcomes in the Swedish National Quality Registers. J Intern Med 279(2):141\u2013153. https:\/\/doi.org\/10.1111\/joim.12409","journal-title":"J Intern Med"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00709-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00709-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00709-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T08:23:17Z","timestamp":1721031797000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00709-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00709-9","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"27 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional ethical board in Stockholm (DNR 2018\/1137-31\/2). The study is based on registry data and no informed consent was needed for the particular study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The time of OE and EH were partly funded by Region Stockholm within a research program that was part of a license agreement between Region Stockholm and the EuroQol Research Foundation. OE and EH have received travel grants from the EuroQol Research Foundation and EH has received research funding from the same organization.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}